无视网膜积液月份数对新生血管性年龄相关性黄斑变性结局的影响:HAWK与HARRIER研究的治疗无关分析
该事后分析汇总HAWK和HARRIER随机临床试验中brolucizumab 6 mg组(n=718)与阿柏西普2 mg组(n=715)的患者水平数据,依据第12至96周无积液访视次数将患者分为5类。第96周时,第4类(15-21次无积液访视)和第5类(22次无积液访视,始终干燥)患者视觉和解剖学结局最佳,第1类(0次,从未干燥)和第2类(1-7次)结局最差;第4和第5类视网膜厚度随时间变异性最低。结论认为负荷期后更多访视无视网膜积液与视觉和解剖学结局呈正相关,与积液类型无关。
要点
- 第96周时第4类(15-21次无积液访视)和第5类(22次,始终干燥)视觉和解剖学结局最佳。
- 第1类(0次无积液访视,从未干燥)和第2类(1-7次)视觉和解剖学结局最差。
- 视网膜厚度随时间变异性在第4和第5类最低。
核心结论
- 负荷期后更多访视无视网膜积液与新生血管性年龄相关性黄斑变性患者视觉和解剖学结局呈正相关,与积液类型无关。
研究设计与样本
- HAWK和HARRIER随机临床试验的事后分析,汇总brolucizumab 6 mg组(n=718)与阿柏西普2 mg组(n=715)的患者水平数据。
- 基于第12至96周数据,按无积液访视次数将患者分为5类,并探索基于积液位置的3种无积液定义。
主要发现
- 第96周时第4类(15-21次无积液访视)和第5类(22次无积液访视,始终干燥)视觉和解剖学结局最佳。
- 第96周时第1类(0次无积液访视,从未干燥)和第2类(1-7次无积液访视)视觉和解剖学结局最差。
- 视网膜厚度随时间变异性在第4和第5类最低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of the total number of fluid-free months after loading on visual and anatomical outcomes in neovascular age-related macular degeneration patients receiving anti-vascular endothelial growth factor therapy. METHODS: This post hoc analysis pooled patient-level data from the brolucizumab 6 mg (n = 718) and aflibercept 2 mg (n = 715) arms of the HAWK and HARRIER randomized clinical trials. Based on data from Weeks 12 to 96, patients were assigned to one of five categories based on fluid-free visits (FFVs; the total number of monthly visits at which they were observed to be without retinal fluid). Three definitions of "fluid-free" were explored based on the location of the fluid observed. RESULTS: Patients allocated to Categories 4 (15-21 FFV) and 5 (22 FFV, always dry) consistently had the best visual and anatomical outcomes at Week 96, whereas patients allocated to Categories 1 (0 FFV, never dry) and 2 (1-7 FFV) consistently had the worst visual and anatomical outcomes. Variability in retinal thickness over time was lowest in Categories 4 and 5. CONCLUSION: Absence of retinal fluid at more visits after loading has a positive association with visual and anatomic outcomes in neovascular age-related macular degeneration patients, regardless of fluid type.
引用
- Eichenbaum D, Brown DM, Ip M, et al. IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies. Retina. 2023. PMID: 36705252. doi:10.1097/IAE.0000000000003699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。